ConductScience.org, home

Paper3324948

On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.

Nutt JG. Ann Neurol, 1987. Cited by 171 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Papers, record 3324948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3324948

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
PubMed
Journal
Ann Neurol
PubMed
Year
1987
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
171
iCite
Relative citation ratio, by iCite
6.88
iCite
Revised in PubMed
2013-11-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nutt JGJ G

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LevodopaMajor topic
Parkinson DiseaseMajor topic
Blood-Brain Barrier
Dose-Response Relationship, Drug
Movement Disorders

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 NS 21062NINDS NIH HHSUnited StatesR01NS021062PubMed and NIH

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 171 citations.

PMIDTitleJournalYearIn PapersSource
42,930,793Heterogeneous Patterns of Wearing-Off in Parkinson's Disease.J Pers Med2026https://conductscience.org/library/papers/42930793PubMed
42,181,371Controlled Maxillofacial Administration of Levodopa in a Patient With Parkinson's Disease: A First-in-Human 24-Hour Follow-Up Study.Cureus2026https://conductscience.org/library/papers/42181371PubMed
40,635,563Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.Mov Disord2025https://conductscience.org/library/papers/40635563PubMed
39,500,970Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson's disease.Sci Rep2024https://conductscience.org/library/papers/39500970PubMed
38,863,783The mechanisms of white matter injury and immune system crosstalk in promoting the progression of Parkinson's disease: a narrative review.Front Aging Neurosci2024https://conductscience.org/library/papers/38863783PubMed
36,229,860Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease?Transl Neurodegener2022https://conductscience.org/library/papers/36229860PubMed
30,802,998Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease.Ann Neurol2019https://conductscience.org/library/papers/30802998PubMed
29,186,917The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.Molecules2017https://conductscience.org/library/papers/29186917PubMed
26,171,276L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study.Parkinsons Dis2015https://conductscience.org/library/papers/26171276PubMed
25,112,783A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters.BMC Complement Altern Med2014https://conductscience.org/library/papers/25112783PubMed
24,323,838Continuous drug delivery in Parkinson's disease.CNS Drugs2014https://conductscience.org/library/papers/24323838PubMed
22,783,173Mathematical insights into the effects of levodopa.Front Integr Neurosci2012https://conductscience.org/library/papers/22783173PubMed
22,135,765Reliability in one-repetition maximum performance in people with Parkinson's disease.Parkinsons Dis2012https://conductscience.org/library/papers/22135765PubMed
21,936,884Validation of 24-hour ambulatory gait assessment in Parkinson's disease with simultaneous video observation.Biomed Eng Online2011https://conductscience.org/library/papers/21936884PubMed
21,080,186Pharmacokinetics of levodopa.J Neurol2010https://conductscience.org/library/papers/21080186PubMed
17,828,529Locomotor response to levodopa in fluctuating Parkinson's disease.Exp Brain Res2008https://conductscience.org/library/papers/17828529PubMed
16,485,914Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.Clin Pharmacokinet2006https://conductscience.org/library/papers/16485914PubMed
16,320,098Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.J Pharmacokinet Pharmacodyn2005https://conductscience.org/library/papers/16320098PubMed
15,502,970Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.Naunyn Schmiedebergs Arch Pharmacol2004https://conductscience.org/library/papers/15502970PubMed
11,548,910Economic and health-related quality of life considerations of new therapies in Parkinson's disease.Pharmacoeconomics2001https://conductscience.org/library/papers/11548910PubMed

See all 39 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3324948

GET https://conductscience.org/api/papers/v1/3324948/cited_by?page=2